Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

33.3%

1 terminated/withdrawn out of 3 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1
2(66.7%)
Early Phase 1
1(33.3%)
3Total
Phase 1(2)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT07414940Phase 1Recruiting

ACTinium in Castrate-RESistant Prostate Cancer After LUTEtium

Role: collaborator

NCT05413850Phase 1Recruiting

Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection

Role: lead

NCT06516510Early Phase 1Terminated

A Dosimetry Study of Lutetium (177Lu) rhPSMA-10.1 and Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto®) in Patients With Non-curative Metastatic Prostate Cancer

Role: lead

All 3 trials loaded